- Business Wire•14 hours agoGenentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan
Genentech, a member of the Roche Group , today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva® plus chemotherapy followed by Gazyva alone head-to-head against Rituxan® plus chemotherapy followed by Rituxan alone for people with previously untreated follicular lymphoma.
- Zacks•3 days ago
Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.
- Zacks•4 days ago
Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.99|
|Dividend & Yield||1.02 (3.74%)|
|1y Target Est||N/A|